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ABSTRACT 
 
Megumi A. Williamson: The Role of IL-29 and IL-28B in the Innate Immune Response 
(Under the direction of Thiago Morelli, Julie Marchesan, Steven Offenbacher, and  
Antonio Amelio) 
 
Aims: Chronic periodontitis (CP) is an inflammatory disease induced by dysbiotic 
biofilm in a susceptible host, resulting in progressive attachment loss, and subsequent alveolar 
bone loss. Recent genome-wide association studies (GWAS) and genome-wide gene centric 
analysis on periodontal complex traits (PCTs) identified possible associations of IL-29 and IL-
28B with periodontal diseases. However, the underlying mechanisms for how these genes 
contribute to the pathogenesis of periodontitis are largely unknown. The aims of the present 
study were to explore the role of IL-29 and IL-28B and their gene polymorphisms in the innate 
immune response by dendritic cells. Materials and methods: To explore the effect of IL-29 on 
the cytokine production in response to TLR4 stimulation, the IL-29 gene was knocked-down in 
THP-1 cells using IL-29 shRNA lentiviral particles. Pro- and anti-inflammatory cytokine levels 
were measured with Luminex® multiplex assay. To assess the effect of genetic variations in IL-
29 and IL-28B, whole blood samples from fifteen subjects (6 subjects with major allele for both 
IL-29 and IL-28B, 5 subjects for major allele in IL-29 and minor allele in IL-28B, and 4 subjects 
with minor alleles for both genes) were collected and CD14+/CD16lo PBMCs were isolated to 
generate DCs. The effect of IL-29 and IL-28B SNPs on TNF-α and IL-10 expression in PBMC-
derived dendritic cells were examined in response to stimulation with ligands of TLR1-2, TLR-2, 
and TLR4 using Luminex multiplex assay. Results: THP-1 cell-derived DCs showed decreased 
expression of TNF-α and IL-10 in IL-29 gene knockdown DCs, compared to DCs transduced 
                                  iv 
with the scramble shRNA control lentiviral clone. IL-28B expression was decreased in IL-29 
knockdown clones, while there was no difference between the scramble and two IL-29 gene 
knocked-down clones. Based on the evaluated samples, SNPs in IL-29 and IL-28B did not affect 
the expression levels of IL-10 or TNF-α in PBMC-derived DCs in response to TLR1-2, TLR2, 
and TLR4 stimulation. Similarly, the expression levels of IL-28A and IL-28B were unaffected 
by these SNPs. Conclusion: While the studied SNPs did not show effect on the evaluated 
cytokines, our results indicate that IL-29 and IL-28B may regulate pro- and anti-inflammatory 
cytokine production in DCs in an autocrine manner.  
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CHAPTER 1: GENETIC FACTORS IN THE PATHOGENESIS OF CHRONIC 
PERIODONTAL DISEASE 
 
Introduction 
Periodontitis is a complex infectious and inflammatory disease of the periodontium that 
lead to destruction of alveolar bone and connective tissue. Though microorganisms in the 
subgingival biofilm are necessary, the risks for periodontal disease are not equal among all 
individuals such that the presentation and severity of chronic periodontal disease can be 
influenced by variable host inflammatory response to bacteria in the dental biofilm. A classic 
longitudinal study by Löe and colleagues demonstrated that periodontitis did not affect the 
population equally regardless of oral hygiene status. 1 Given that there was no access to dental 
care in this particular population, the results indicated that there was a certain group of 
individuals who are more susceptible to develop periodontal disease. Host susceptibility to 
chronic periodontitis is attributed to individual life style, systemic diseases, and host immune 
responses that are largely influenced by genetic factors. Although environmental variation seems 
to plays a role in a great extent in the inherited susceptibility of chronic periodontitis, 2  
Michalowicz and colleagues estimated that 50% of the expression of chronic periodontitis in 
families is attributed to genetic factors. 3  4 More recently, a large, population-based study on the 
effects of genetic and environmental factors on tooth loss and periodontal disease was published 
by a Swedish group using a total of 10,578 twin pairs with ages 42 years and older (1567 
monozygotic and 2127 dizygotic female pairs, 1180 monozygotic and 1696 dizygotic male pairs 
and 4008 unlike-sex dizygotic pairs).  5  It was estimated that heritability of periodontal disease 
 2 
was 39% and 33% for women and men, respectively, while non-shared environmental factors 
were responsible for the remaining variation. Although there is a range for the heritability 
depending on the study design or periodontal disease definition, these studies support the 
evidence for the involvement of genetic factors in periodontal disease heritability. As a 
consequence, great interest has been directed toward identifying genes and genetic variations in 
association with periodontal disease, which will provide a basis for the development of better 
genetic screening of the risks for periodontal disease as well as better treatment strategies. 
Host immune response and genetic factors in periodontal disease pathogenesis 
Growing evidence has supported the roles of genes and their polymorphisms in affecting 
host response to oral microbes that are involved in the pathogenesis of chronic periodontal 
disease. 6  7  Gene polymorphisms are allelic variants of a gene that occurs in at least 1% of the 
population, involving a change from one of the four nucleotides to another. Although gene 
polymorphisms are typically considered normal variants of the population, changes in nucleotide 
can alter the amino acid composition coded by the codon, resulting in increased/decreased 
expression or dysfunction of protein.  
Nikolopolous and colleagues performed meta-analysis on the involvement of 6 cytokine 
polymorphisms in the risk of either chronic or aggressive using a total of 53 studies including 
4178 cases and 4590 controls. 7  Their result indicated that a moderate positive association 
between the IL-1A-889T variant and chronic periodontitis in Caucasians and elevated risk for 
chronic periodontitis of IL-1B 3953/4T carriers, particularly in Asian-descent individuals, 
suggesting that some cytokine gene polymorphisms are associated with modest increase in the 
probability of developing periodontal disease. More recently, a systematic review on candidate 
gene studies including a total of 124 candidate gene and genome-wide studies evaluated the 
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associations between gene variation and periodontitis. 8  Strong association of SNPs in vitamin D 
receptor, FC-γRIIA, and IL-10 with chronic periodontitis were identified, while a moderate 
association with chronic periodontitis was identified for Toll-like receptor 4, TNF-α, IL-1 α, IL-1 
β, IL-4, MMP9, and MHC in Caucasians and COX2, TNF-α, IL-1 β, IL1VNTR, IL-8 and 
FBXO38 in Asians. Weak association of following gene variants was found: CDKN2BAS, 
DEFB1, PTGS2, MICA-TM, NR1I2, IL-8 and IL-6. However, associations within these genes 
were often observed for different SNPs as well as in different populations.  Furthermore, in 
general, most candidate studies have heterogeneity in case definition, control selection, genetic 
marker selection, and in particular, sample size, which make it difficult to draw conclusive 
association of SNPs with chronic periodontitis. Furthermore, in these candidate gene studies, 
genes are selected based on the current knowledge. There are hundreds of genes, which may have 
an influence on the disease, will not be selected because their functions are unknown or those 
undiscovered genes lie within pathways that have not yet been implicated with the disease. Due 
to these limitations, Genome-wide association studies have become popular in recent years.  
Genome-wide association study (GWAS) is a powerful tool for identifying genetic 
variation across the entire human genome in associations with observable traits or the presence 
or absence of a complex disease or condition including chronic periodontitis. According to the 
GWAS catalogue (the NHGRI-EBI Catalog of published genome-wide association studies, 
https://www.ebi.ac.uk/gwas/), a total of 1960 GWA studies had been published by the end of 
2013. As for periodontal disease related GWAS, there are a total of 14 GWAS on both 
aggressive and chronic periodontitis or periodontitis disease phenotypes published by the end of 
2017. Unlike candidate gene studies, GWA studies are hypothesis free. Although the real 
contribution of novel genetic markers identified via GWAS may require additional extensive 
 4 
replication, exploration and validations, GWAS enables to assess a large number of genes with 
possible association with diseases or disease phenotypes.  
In 2009, the first GWAS was carried out on aggressive periodontitis using European 
descent, and identified a risk locus, rs1537415, that was significantly associated with the disease 
populations. 9  This SNP was located in the intron of glycosyltransferase 6 domain containing 1 
(GLT6D1), and the rare G allele of rs1537415 showed an enrichment of 10% in periodontitis 
cases. This association implicates that rs1537415 as an important genetic susceptibility factor.  
Following years, several GWA studies on aggressive and chronic periodontitis had been 
published. Divaris and colleagues employed GWAS of chronic periodontitis in a cohort of 4504 
European Americans participating in the Atherosclerosis Risk in Communities (ARIC) study, 
and found suggestive evidence of association for six loci, including NIN, NPY, WNT54A for 
severe chronic periodontitis and NCR2, EMR1, and 10p15 for moderate chronic periodontitis. 10  
However, the association of these loci in chronic periodontitis did not reach genome-wide 
significance, possibly due to the fact that GWAS has typically low power to detect small genetic 
effects and relatively small to moderate sample size and inability of currently applied phenotype 
case definitions to fully capture disease expression patterns. The same group conducted another 
GWAS to explore genetic risk loci for colonization with subgingival periodontal microbiota 
using 1020 white participants of the ARIC study.11 Among those 2.5 millions of examined gene 
loci, none of the loci met genome-wide significant association in the colonization pattern, while 
stronger signals were found for five loci in Red-complex trait, 3 in Orange complex trait, and 2 
for aggressive periodontitis. These studies led to further exploration of genetic risk loci in 
chronic periodontitis. Later, using the same cohort as in the first report by Divaris and 
colleagues, a MAGENTA approach (meta-analysis gene set enrichment of variant associations) 
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was employed to obtain gene-centric association results corrected for gene size, number of SNPs, 
and local linkage disequilibrium. 12  Six suggestive loci were found to be significantly associated 
with chronic periodontal disease: 4 loci (NIN, ABHD12B, WHAMM, AP3B2) were associated 
with severe chronic periodontitis and 2 loci with high periodontal pathogen colonization 
(KCNK1 for red-complex, and HGD for P. gingivalis). 10  These results offered novel insights 
into candidate genes, possible gene sets, and pathogenesis of chronic periodontitis.   
In a recent study by Offenbacher and colleagues, periodontal complex traits (PCTs) were 
defined by microbial composition data (DNA checkerboard quantification of 8 periodontal 
pathogens), protein level of IL-1β as an inflammatory mediator in gingival crevicular fluid 
(GCF), and clinical disease classification  (CDC/AAP chronic periodontal disease classification) 
of 975 Caucasian subjects. 13  Six disease associated PCTs were described as follows: PCT1 has 
a microbial community structure that has a high correlation and positive loading with all 
pathogens in red and orange complex originally identified by Socransky and colleagues. 14  
Based on the microbial composition, this trait was also called Socransky trait, and was the most 
common trait among the other complex traits (proportion of variance 0.465). PCT2 presents 
severe periodontal disease while weak positive loading of P. gingivalis (P.g) and IL-1β.  PCT3 is 
characterized by positive loading of GCF-IL-1β and A. actinomycetemcomitans (A.a trait). PCT4 
shows mixed bacterial profile with high positive loading of GCF-IL-1β and weak positive 
loadings of P. nigrescens, P intermedia, and T. denticola and low levels of A.a. PCT5 (P.g trait) 
is associated with the highest loading of P.gingivalis. PCT6 is not positive for examined 
pathogens or IL-1β, but has a positive association with CDC/AAP entry and severe clinical 
categories as well as highest association with smoking and diabetes. GWAS on these complex 
traits identified ten candidate gene loci, and of those, 6 loci were associated with PCT1 
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(Socransky trait), 2 loci for PCT3 (A.a trait), and 1 locus for PCT4 and 3 loci for PCT5 (P.g 
trait). In addition, genome-wide gene-centric association analysis for the six disease-associated 
PCTs was employed using MAGENTA, which examined for significant gene-centric 
associations by correcting for the gene size that includes a 110kb upstream and the 40kb 
downstream region, the number of SNPs within the gene region, and the local linkage 
disequilibrium characteristics, and demonstrated that 80 genes in 37 loci were significantly 
associated with the complex traits including IL-29 (IFN-λ1) and IL-28B (IFN-λ3) with a 
significant association with PCT1. Gene centric association analysis suggested that IFN-λ1 and 
IFN- λ3 were significantly associated with moderate to severe periodontal disease characterized 
by interproximal clinical attachment loss of 3 mm or greater. An impact of SNPs in IFN-λ 
signaling cascade has been described in several studies that these SNPs are associated with 
important clinical phenotypes in the context of infectious disease. Thus, these genetic variants 
confer risk for severe disease that is exacerbated in the presence of high levels of periodontal 
pathogens. 
Significance of IL-29 and IL-28B in infectious disease 
The type III interferon family, composed of IFN-λ1, IFN-λ2, IFN-λ3 (previously called 
IL-29, IL-28A and IL-28B, respectively), was first discovered in 2003 as a newly identified IL-
10 cytokine family. 15 16  More recently, an additional gene in IFN-λ family was discovered in a 
previously unrecognized transiently induced region upstream of IFL-λ3, and was later named 
IFN- λ4. 17  The genes encoding human IFN-λ family are located on chromosome 19q.13.13. The 
mechanisms underlining IFN-λ production involve pattern-recognition receptors such as TLRs, 
C-type lectin receptors like dectins, and retinoid-acid inducible gene 1 (RIG-1) family members.  
Viral infection induces the expression of IFN-λs in a variety of cell types including 
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epithelial cells in respiratory system and intestine.18 mRNAs for these cytokines were expressed 
low to undetectable level, but it increased through stimulation with toll-like receptor 3 agonist 
(poly I:C, an inducer of type I IFN) and encephalomycarditis virus (EMCV) in variety of cell 
types including human peripheral blood mononuclear cells (PBMCs). 15  This study also 
demonstrated that pretreatment of HepG2 cells with IFN- λ2 and IFN- λ1 were able to protect 
these cells from viral-induced cytopathogenic effect, indicating that IFN- λ have direct antiviral 
activity.  
In addition to the involvement of IFN-λs in viral infection, several in vitro studies have 
reported that the induction of IFN-λs takes place in bacterial infections. For example, 
lipopolysaccharide (LPS) from the outer membrane of Gram-negative bacteria induces the 
expression of IFN-λs, mainly in DCs. 19 20 21 The induction of IFN-λ in dendritic cells after LPS 
stimulation in vitro suggest the role of IFN-λs in antibacterial defense. IFN-λs are involved in the 
differentiation and maturation of dendritic cells PBMCs. Langerhans cells (immature dendritic 
cells) take up pathogens that they encounter in the tissue through TLRs, and induce activation 
and maturation process of DCs. While DCs do not express mRNA for IFN-λs at immature stage, 
once dendritic cells are activated and the maturation process takes place, DCs modifies their 
capacity to produce cytokines and IFN-λs. Interestingly, PBMC-derived DCs produced different 
mRNA expression levels for several cytokines of IL-10 IFN family including IFN-λs, depending 
on the maturation stimuli. 21  While there was no mRNA expression for IFN-λ1 in DCs matured 
with TNF-α/IL-1β, CD40L/IFN-γ and LPS maturation induced IFN-λ1 expression with the 
highest in DCs with LPS maturation. Furthermore, IFN- λ1 promotes LPS/TLR4 mediated 
inflammation by enhancing TLR4 expression and the production of inflammatory cytokines (IL-
6, IL-8 and TNF-α).22  
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Many periodontal pathogens in the subgingival biofilm such as P. gingivalis or A. 
actinomycetemcomitans, for example, are Gram-negative bacteria and express LPS on their outer 
membrane. It is therefore speculated that periodontal pathogens activate innate immunity through 
TLRs on antigen-presenting cells, and induce expression of IFN-λs within oral epithelium. As 
shown in the study by Offenbacher and colleagues, gene-centric association analysis suggested 
the association of severe periodontal disease and SNPs for IFN-λs. One can reasonably assume 
that IFN-λs are induced in DCs through challenge with periodontal pathogens in the oral 
environment, and gene variation of IFN-λs may alter the innate immune response in the 
periodontal disease.  
IFN-λs exert their function through a common heterodimeric transmembrane receptor 
complex composed of the cytokine receptor family class II members IFN-λR1 (also called IL-
28RA and IL-28R1) and IL-10R2 (also called IL-10RB), which is expressed in cells of epithelial 
origin. Following activation of IFN pathway, an autocrine or a paracrine signaling network 
mediates the cellular response, primarily JAK/STAT pathway.  Activation of JAK/STAT 
signaling cascade induces hundreds of IFN-stimulated genes (ISGs). Although the main producer 
for IFN-λ is DCs, cells of epithelial origin are considered as the primary targets because they 
express significant levels of IFN-λR1, 23  suggesting the possible roles of IFN-λ produced by 
DCs in the homeostasis or pathologic changes of oral epithelium under the exposure to 
commensal and pathogenic microorganisms. Besides the epithelial cells, B-cells are also the 
target cells of IFN-λs, potentially modulating the adaptive immune functions through DCs 
maturation, and subsequent priming, activation, and proliferation of pathogen-specific B-cells. 
Groen and colleagues demonstrated the ability of IFN-λs to enhance TLR-induced responses in 
B-cells, especially attributed to an upregulation of TLR-7, and enhance their capacity to produce 
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immunoglobulins. 24    
Intriguingly, several studies have shown the involvement of IFN-λ in the central nervous 
system and placenta, both of which have been studied in association with periodontal disease that 
is accompanied with translocation of periodontal pathogens in these organs. In the central 
nervous system (CNS), IFN- λ3 exerts indirect antiviral activity independent of signal transducer 
and activator of transcription 1 (STAT1) independent manner thereby protecting CNS from virus 
infection. A noncanonical IFN- λ3 signaling via IFN-λR1 enhances blood-brain-barrier (BBB) 
integrity by increasing transendothelial electrical resistance (TEER) across the brain 
microvasculature endothelial cells (BMECs), thereby reducing virus movement across the 
barrier.  25  Furthermore, LPS pre-treatment of hCMEC/D3 cells (blood-brain-barrier cell line, 
human temporal robe microvessel origin) decreased TEER, resulting in greater crossing of virus 
through the cells in vitro, which was further confirmed by in vivo study in mice that tissue 
permeability induced by LPS pretreatment was reversed by IFN-λ3 administration. In vivo study 
showed that IFN-λ2 and IFN-λ3 mRNA and IFN-responsive genes IFIT1 and Mx1/2 were 
increased in the placenta infected with L. monocytogenes via venous inoculation in mice. 
Whether this expression of IFN-λs could mediate protection of the fetus from bacterial infection 
or whether this pathway is helping pathogens to invade into the host and stimulate abortion needs 
further investigation. 26 Since bacterial infection can trigger the expression of IFN- λ, it would be 
interesting to explore the possible mechanisms on how IFN- λ modulate epithelial homeostasis 
or pathologic change in these organs in association with periodontal disease. 
The Role of Dendritic Cells in the Innate Immune Response 
The innate immune system is mediated by physical barrier, secretory molecules, and 
cellular elements represented by neutrophils, macrophages and dendritic cells (DCs). Among 
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these cells, DCs serve as the most potent antigen-presenting cells: DCs capture antigens through 
variety of pattern-recognition receptors, through which they further differentiate into mature 
DCs. Mature DCs present antigens to prime naïve T-cells, thereby linking innate immune 
response and adaptive immune response.  
DCs are scattered heterogeneously in lymphoid and non-lymphoid tissues with a different 
morphology, phenotype, and function depending on the state of maturation of DCs. Within the 
oral epithelium, Langerhans cells and DCs are ubiquitously distributed within the oral 
epithelium, suggesting that they play a critical role in the epithelium. In healthy epithelium 
(symbiotic environment), DCs are present in an immature state, and are highly phagocytic and 
responsive to the accumulation of microbial biofilm. 27  DCs capture and process both 
commensal and pathogenic microorganisms through the binding of bacterial structures called 
pathogen-associated molecular patterns (PAMPs) by pattern recognition receptors (PRRs) such 
as toll-like receptors (TLRs) either alone or in heterodimerization with other TLR or non-TLR 
receptors. TLRs recognize specific PAMPs: peptidoglycan, lipoproteins, and zymosan are 
recognized by TLR2, double-stranded RNA (from virus) by TLR3, LPS and heat-shock proteins 
by TLR4, flagellin by TLR5 and CpG (DNA strands of cytosine, purine and guanine) motif of 
bacterial DNA by TLR9.  
Several studies have reported the expression and function of DCs in the oral mucosal 
disease including periodontal disease. In the oral mucosae, three main types of DCs, Langerhans 
cells (immature DCs), submucosa DCs (maturing DCs), and plasmacytoid DCs (mature DCs), 
are arranged in such a way that can efficiently detect oral microbes and present antigen to the 
other immune cells. In healthy periodontium, Langerhans cells (immature DCs) were 
predominantly expressed in the epithelium, but in periodontal disease condition, Langerhans 
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cells increase in number and migrate into deep connective tissue. 28  As periodontal disease 
progresses, with the increase in the pro-inflammatory cytokines in the environment, Langerhans 
cells become mature and start expressing CD80, CD83, CD86, CD1a, HLA-DR, or MHCII, 
markers for mature DCs. Mature DCs also express various molecules that are important in the 
specific antigen recognition through interaction of the peptide-antigen-MHC molecule on DCs 
with the T-cell receptor, and costimulation molecules that will aid more efficient antigen 
presentation from DCs to T-cells. These mature DCs play a role in the formation of lymphoid 
foci interproximally around the teeth in periodontal disease, and elicit T-cell response locally as 
potent antigen-presenting cells. Mature DCs further migrate into secondary lymphatic organs 
where they present antigens and prime T-cells. In the experimental gingivitis case, as plaque 
accumulated, Langerhans cells continued to increase in the gingival epithelium from health to 
gingivitis to periodontitis, 28  29  30  Decreased Langerhans cells in the late phase of experimental 
gingivitis indicate that in the course of inflammatory response, DCs change it’s phenotype from 
immature to mature DCs. 
As shown in the previous study by Wolk and colleagues,21 TLR activation through 
bacterial challenge induces the expression of IFN-λs in DCs during the maturation process. IFN-
λs produced during DC maturation upregulated TLR2 and TLR3 in the keratinocytes, and the 
sensitivity towards TLR ligands, suggesting that IFN-λs is involved in an elevated recognition of 
and defense against various pathogens. Together with the results from GWAS, it is hypothesized 
that IFN-λs are involved in the innate immune response by DCs in the oral epithelium and 
modify the function of neighboring tissue cells as well as the activation of adaptive immunity. 
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CHAPTER 2: THE EFFECT OF IL-29 GENE SILENCING IN THP-1 CELL-DERIVED 
DENDRITIC CELLS AND THE EFFECT OF Il-29 and IL-28B GENE 
POLYMORPHISMS ON THE INNATE IMMUNE RESPONSE 
 
Introduction  
Periodontitis is an inflammatory disease of the periodontium, characterized by 
destruction of connective tissue attachment and supporting alveolar bone. As periodontal 
diseases are often silent in early stage, patients experience only minimal to no symptoms. This is 
contributing to the high prevalence of periodontal disease. NHANES reported that the prevalence 
of periodontal disease is as high as 47% in the population over 30 years of age in the US. 1  
Though the primary etiology of periodontal diseases is microbial biofilm, other risk factors such 
as host immune response, genetic, and environmental factors are highly attributable in the 
pathogenesis of periodontal diseases. 
Growing evidence suggests that genetic variation contributes significantly to host 
inflammatory response, thereby influencing host susceptibility to periodontal disease 
development. 2  3  Several genome-wide association studies on periodontal disease have been 
published in recent years, and NPY, CAMTA1/VAMP3, ANRIL and GLT6D1 are found to be 
true genetic susceptibility factors.  4  5  6  7  8  9 In a recent study by Offenbacher and colleagues, 
periodontal complex traits (PCTs) were defined based on the clinical data as well as the 
subgingival microbial composition and IL-1β in gingival crevicular fluid (GCF) via principle 
component analysis (PCA). Of those, PCT1 was associated with severe periodontitis and highly 
loaded with all periodontal pathogens assessed. In that study, a total of ten risk loci were found 
to be statistically significantly associated with periodontal complex traits: 6 risk loci were 
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associated with PCT1, 2 loci for PCT4 and 3 loci for PCT5. Gnome-wide gene-centric 
association analysis for the first six periodontal complex traits was performed using Meta-
Analysis Gene-set Enrichment of Variant Associations (MAGENTA), and eighty genes in 37 
loci were found to be significantly associated with PCTs. Of those eighty genes, IL-28B (IFN-
λ3) and IL-29 (IFN-λ1) were significantly associated with PCT1 trait with gene rank of 13th and 
18rh, respectively, and IL-29 was found to be one of the lead SNPs in the chromosome 19 that 
was significantly associated with severe periodontal disease.  
IL-29 and IL-28B belong to type III interferon (IFN) family (also called interferon-λ 
family) and are distantly related to IL-10 interferon family. There are 4 members identified in 
this Type III interferon family: IFN-λ1 (IL-29), IFN-λ2 (IL-28A), IFN-λ3 (Il-28B) and IFN-λ4. 
Much of work on the type III interferon as well as their SNPs has focused on the regulation of 
their expression and function during viral infections. However, recent studies have also reported 
their role in the bacteria-host interactions. In bacterial infection, the activation of toll-like 
receptors (TLRs) in dendritic cells plays a critical role in the expression of type III interferon. 
The oral epithelium receives continuous bacterial challenge where DCs constantly survey 
invading pathogens in the epithelial tissue. Given the fact that DCs are the main source of type 
III interferon and that their receptor complex are preferentially expressed in the cells of epithelial 
origin, it is speculated that IL-29 and IL-28B are involved in the innate immune response via 
dendritic cells. Furthermore, the presence of SNPs in IL-29 and IL-28B may affect the function 
of DCs in the innate immune response. 
The aim of this study was to explore the effect of shRNA-induced IFN λ1 (IL-29) gene 
silencing in the pro- and anti-inflammatory cytokine production in THP-1 cell-derived DCs upon 
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challenge with TLR ligands. We also want to explore the effect of gene polymorophisms of IL-
29 and IL-28B genes in cytokine production by DCs after LPS challenge. 
Materials and Methods 
Study population 
A total of 200 European American volunteers, who were enrolled in ARIC study 
previously, were screened, and a total of 15 subject who satisfied inclusion and exclusion criteria 
participated in the study (table 1 and figure 2). All recruitment plans including advertising, email 
postings, and flyers were approved by the IRB. All participants were explained of the trial 
including information on the objectives, potential benefits, risks, and inconveniences, and signed 
consents approved by the Institutional Review Board of the University of North Carolina at 
Chapel Hill. After genotyping each participant, a total of twenty-four European American 
subjects between ages of 25 and 71 years (mean 42 years old) were selected. Subjects were 
divided in 3 groups based on the SNP variants: major allele for IL-29 and major allele for IL-
28B, major allele for IL-29 and minor allele for IL-28B, and minor allele for IL-29 and IL-28B. 
An individual who meets any of the following criteria will be excluded from participation in this 
study: subjects must have read, understood and signed an informed consent form in English, 
subjects must be able and willing to follow study procedures and instructions in English, subjects 
must be non-Hispanic Caucasian, subjects must be adult males or females with a minimum of 25 
years (inclusive), subjects must present with at least 20 teeth in the functional dentition, 
excluding third molars, Subjects must have at least 3 teeth in each posterior sextant and Subjects 
must be in good general health. Exclusion criteria include chronic disease with oral 
manifestations including diabetes mellitus, current smoker or one that has stopped smoking less 
than 2 years prior to enrollment, gross oral pathology other than the periodontal disease, 
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treatment with antibiotics for any medical or dental condition within one month prior to the 
screening examination, chronic treatment (i.e., two weeks or more) with any medication known 
to affect periodontal status (e.g., phenytoin, calcium antagonists, cyclosporin, coumadin, non-
steroidal anti-inflammatory drugs, aspirin) within one month of the screening examination, 
ongoing medications initiated less than three months prior to enrollment (i.e., medications for 
chronic medical conditions must be initiated at least three months prior to enrollment), 
significant organ disease including impaired renal function, heart murmur, history of rheumatic 
fever or valvular disease, or any bleeding disorder, Infectious diseases such as hepatitis, HIV or 
tuberculosis, anemia or other blood dyscrasias, anticoagulant therapy or drugs, such as heparin or 
warfarin, severe unrestored caries, or any condition that is likely to require antibiotic treatment 
over the trial, pregnant, or expect to become pregnant within the next several months, females of 
child-bearing capacity must be willing to have pregnancy test to confirm they are not pregnant, 
and anything that would place the individual at increased risk or preclude the individual’s full 
compliance with or completion of the study.  
Subjects’ recruitment and retention  
Subjects that become patients of the General and Oral Health Center are eligible for care 
within the clinic that can extend beyond that provided under protocol, as well as referrals to other 
dental clinics within the school as appropriate. Monetary compensation was offered for 
participation in the study. Dental treatment was offered to each study participant according to 
his/her level of need. Study participants were called by phone and/or emailed depending upon 
their indicated preferred contact method to be reminded of planned study visits or to reschedule 
missed study visits.  
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Subjects’ withdrawal  
Subjects were allowed to withdraw from the study at any time at their own request, or 
they may be withdrawn at any time at the discretion of the Investigator for safety, behavioral or 
administrative reasons. If a participant withdrawn consent, no further evaluations was performed 
on that participant and no attempts was made to collect additional data regarding that participant. 
If a participant failed to present for a scheduled study visit, study staff attempted to reschedule 
the participant utilizing the means of contact provided by the participant. 
Genotyping for SNPs in IL-29 and IL-28B 
 A total of four SNPs were selected based on genome-wide gene-centric analysis by 
Offenbacher and colleagues (table 2 and figure 1): 1 missense SNP for IL-29 (rs30461), and 3 
SNPs for IL-28B. One of them was located upstream of IL-28B (rs8099917), while 2 SNPs were 
located on the downstream side (rs8105790 and rs11083519). Saliva sample was collected to 
determine the SNP variations for IL-28B (rs8105790, rs11083519, rs8099917) and IL-29 
(rs30461) from each participant (table 2). Unstimulated whole saliva, a total of 4mL was 
collected from each subject as previously described by Mandel. The samples were stored at -
80°C until use. Genomic DNA was extracted from saliva samples using a DNeasy kit (QIAGEN, 
Hilden, Germany). Forward and biotin-labeled reverse primers for target fragments were 
designed by Assay Design Software 2.0 (table 3). Target fragment was amplified via PCR.  The 
amplification conditions for rs8105790, rs11083519 and rs8099917 were an initial denaturation 
at 95°C for 15 minutes; 45 amplification cycles of 94°C for 30 seconds, 57°C except rs30461 for 
30 seconds, and 72°C for 30 seconds; and a final extension step at 72°C for 10 minutes. For 
rs30461, primer annealing temperature was set at 55°C. The correct size of amplified PCR 
products were confirmed by agarose gel electrophoresis (figure 3). 
 20 
 Subsequently, pyrosequencing was performed following the manufacture’s protocol. 
Briefly, 10µl of biotinilated PCR product from each subject was mixed with 30µl of nuclease 
free water, and immobilized by mixing with 2µl of streptoavidin-coated sepharose beads, 
followed by an addition of 40µl of PyroMark binding buffer (QIAGEN, Hilden, Germany). 
Samples were placed in a 96-well PCR plate. Samples were then analyzed with the PyroMark 
Q96 Vacuum Workstation (QIAGEN). Sepharose beads containing immobilized PCR products 
was captured onto PyroMark Vacuum Prep Filter Probes, denatured in denaturing solution, 
washed in washing buffer, and then release the beads in 96-well plate containing 3.6pmol 
sequencing primers in 12µl PyroMark annealing buffer. Plate was heated at 86°C for 2 minutes 
to denature the PCR products, and left at room temperature for 5 minutes to allow the annealing 
of the sequencing primers. The plate was loaded onto a PSQ HS 96 Pyrosequencing System. The 
sequence was determined by Pro Gold CDT reagents. The presence of variation or the copy of 
the minor allele was determined by the pyrogram pattern based on the peak height. 
Preparation of IL-29 shRNA lentiviral clones 
IFN λ1 knockdown cells of the human acute monocyte leukemia cell line, THP-1 cell 
lines, were established using stable expression of short heparin RNAs (shRNAs) that target IFN 
λ1 mRNA. Four different pre-designed shRNA interference (RNAi) constructs for IFN-λ1 were 
chosen (Sigma-Aldrich, St. Louis, MO). Accession number of target gene is NM-172140, and 
oligo clone numbers for shRNA closes for IFN- λ1 are TRCN0000058243, TRCN0000058244, 
TRCN0000058245, TRCN0000058246 (Table4). The plasmids containing the pLKO.1 
expression vector carrying a cloning site between AgeI and EcoRI  for the shRNA sequences 
with a puromycin resistance marker for selection. As a negative control, pLKO.1-TRC cloning 
vector containing scramble shRNA was used (AddGene, Cambridge, MA). Pakaging shRNA-
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encoding Lentivirus was performed at Lenti-shRNA Core Facility 
(http://www.med.unc.edu/lenti-shrna). After obtaining the bacterial glycerol stocks from the 
Lenti-shRNA Core facility, cloning vectors were amplified through Midipreparation (QIAGEN). 
Viral supernatant was collected by the Core facility and aliquoted in the eppendorf tubes and 
stored at -80°C until use.  
Quantitative reverse transcription polymerase chain reaction (qRT-PCR) 
Previous studies have shown that IFN-λ1 expression is limited without viral or bacterial 
infection in THP-1 cells. LPS at a concentration of 100ng/ml was used to induce IFN-λ1 mRNA 
in THP-a cell-derived DCs and the silencing efficiency of each clone was analyzed via qRT-PCR. 
Total RNAs were collected from the cells using RNeasy Mini Kit (QIAGEN, Veranda, CA), and 
RNA concentrations were determined with NanoDrop Spectrophotometer (Thermo Fisher 
Scientific). cDNAs were synthesized from 200ng of total RNA with SuperScript VILO master 
mix (Invitrogen) with  MMRV reverse transcriptase and stored at -80°C.  cDNAs were thaw on 
ice, completely resuspended by gentle pipetting, then briefly centrifuge to bring liquid to the 
bottom of the tube. Add 20x TaqMan® Gene Expression Assay, 2x TaqMan® Gene Expression 
Master Mix (Applied Biosystems) at a final concentration of 1x for each, 200ng cDNA and 
RNase-free water, mix gently by pipetting and centrifuge the tubes briefly. Transfer 20uL of 
PCR reaction mix into each well of 96-well reaction plate. The plates containing samples were 
covered with qPCR plate seals (Absolute qPCR Plate Seals, ThermoFisher Scientific), and were 
analyzed on Applied BIosystems Real-Time PCR system. Amplification plots for the entire plate 
were viewed, and the baseline and threshold values were set to determined the mRNA levels. 
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Cell Culture 
 THP-1 cell line: The human monocyte cell line from an acute monocytic leukemia, 
THP-1 cells were cultured in Rosewell Park Memorial Institute 1640 (RPMI1640) cuture 
medium (Gibco Gaithersburg, MA) with 10% fetal bovine serum (FBS; Gibco), 100 unites/mL 
penicillin, 100µg/mL streptomycin and 10mM HEPES buffer at 37°C in a humidified 5% CO2 
incubator prior to transduction.  
 THP-1 cells were transduced with IFN-λ1 shRNA lentiviral particles or control 
lentiviral particles (MISSION® pLKO.1-puro Non-Target shRNA control, SHC016V; Sigma-
Aldrich). Initially, optimal concentration of puromycin dihydrochloride (Sigma-Aldrich) 
required to kill 100% THP-1 cells was determined. The cells were incubated in 10mL of culture 
medium with or without puromycin at concentration of (range 0.5 –10 µg/mL) for 48 hours. The 
medium was changed every 3 days. Cell survival was assessed by manual count on 
hemocytometer at the same time of medium change. After 3-5 days of puromycin selection, most 
of the cells were found to be dead at a concentration of 1.5µg/mL puromycin. 150µl viral stock 
for each clone was added to THP-1 cells in 10 ml of culture medium. Transduced cells were 
allowed to proliferate with repeated passages under the presence of puromycin until a sufficient 
cell number was achieved for puromycin selection. Culture medium was replaced with fresh 
medium with 1.5 µg/mL puromycin every 2-3 days until resistant clones were selected. 
Transduced THP-1 cells were allowed to grow for 1-2 weeks and stored in liquid nitrogen until 
use. 
 IFN-λ1 shRNAs transduced THP-1 cells were thawed and harvested by 
centrifugigation, and resuspended in the culture medium RPMI1640 (GIBCO, Gaithersburg, 
MA) containing 100IU/mL of penicillin, 100µg/mL of Streptomycin, and 10mM HEPES but 
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without 10% FBS (GIBCO). To differentiate THP-1 cells into DCs, previously transduced and 
puromycin selected THP-1 cells were plated in 24-well plate at 500,000 cells/well (1ml/well), 
and cultured in the same culture medium with 1500IU/mL of recombinant human IL-4 and 
1500IU/mL of recombinant human GM-CSF in humidified 5% CO2 incubator at 37°C for 5 days. 
Medium change was performed every 2 days. At day 5, media was replaced with fresh media 
containing 3000IU/mL of recombinant human IL-4, 1600IU/mL of recombinant human GM-
CSF, 2000IU/mL of recombinant human TNF-α, and 200ng/mL of ionomycin, and cultured in 
the 5% CO2 incubator at 37°C for additional 2 days for maturation of THC-1 cell derived 
immature DCs. Cells were then stimulated with TLR-4 ligand (100ng/mL LPS from E. coli; 
InvivoGen, San diego, CA) in the humidified 5% CO2 incubator at 37°C for 6 hours. After 
stimulation, supernatant was collected, and total RNAs were collected from the cells using 
RNeasy Mini Kit (QIAGEN) for qRT-PCR. 
PBMC: A total of 50mL of whole blood was collected from each subject by qualified 
phlebotomist via standard venipuncture technique. Whole blood was diluted in cold 1x DPBS 
(GIBCO, Gaithersburg, MD), and PBMCs were separated by Ficoll® Paque Plus (GE 
Healthcare, Milwaukee, WI) density gradient centrifudigation, and frozen in a mixture of 90% 
heat-inactivated fetal bovine serum (FBS, GIBCO, Gaithersburg, MD) and 10% dimethyl 
sulfoxide (DMSO, Molecular Probes™, Eugene, OR) in liquid nitrogen until use. CD14+/CD16lo 
monocytes were isolated from thawed PBMCs by negative selection using Dynabeads™ 
Untouched™ Human Monocytes kit (Invitrogen, Carlsbad, CA). Purity of monocytes was 
assessed by flow cytometric analysis (see below). CD14+/CD16lo monocytes were plated at 
500,000 cells/well in the 24-well cell culture plate (Corning® Costar® TC-Treated Plates, 
Corning, NY) with 500µL of RPMI1640 medium (GIBCO, Gaithersburg, MD) containing 10% 
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FBS (GIBCO, Gaithersburg, MD) and Penicillin-Streptomycin (GIBCO, Gaithersburg, MD) at a 
final concentration of 100U/mL of penicillin, 100µg/mL of Streptomycin. To induce 
differentiation of PBMCs into immature dendritic cells, 1000IU/ml of human recombinant 
Granulocyte Macrophage-Colony Stimulating Factor (rhGM-CSF, PeproTech, Rocky Hill, NJ) 
and 500IU/ml of recombinant human IL-4 (PeproTech, Rocky Hill, NJ) were added to the media, 
and cultured in the 5% CO2 incubator at 37°C for 6 days. To induce maturation, cells were then 
cultured with 100ng/ml of lipopolysaccharide (LPS) from Escherichia coli from Human TLR1-9 
Agonist Kit (Invivogen, San Diego, CA) in the continuous presence of GM-CSF and IL-4 for 2, 
6 and 18 hours to achieve different maturation levels of DCs. Use of LPS for maturation was 
determined by the previous in vitro study showing that maturation with LPS yielded the highest 
IFN-λ production. Maturing dendritic cells at each time point were then allowed to rest for 48 
hours in the continuous presence of GM-CSF and IL-4 but without LPS prior to the final 
stimulation, and subsequently maturing dendritic cells were stimulated for 6 hours with selected 
Toll-like receptor (TLR) ligands (InvivoGen): TLR1-2, TLR2 and TLR4.  
Flow cytometric analysis 
 After the isolation of PBMC using Dynabeads Untouched Human Monocytes kit, 
50µL of cell suspension containing at least 100,000 cells was placed in the eppendorf tubes. 
Subsequently, APC anti-human CD14 antibody (BioLegend, San Diego, CA) and/or PE anti-
human CD16 antibody (BioLegend, San Diego, CA) were added to the cells at a concentration of 
5µL/million cells each, incubated for 30 minutes on ice. For negative control, cells were 
incubated in the Flow Cytometry Staining Buffer without addition of antibodies. After the 
incubation, cells were washed in Flow Cytometry Staining Buffer, centrifuged at 600G for 5 
minutes, and remove supernatant. Fresh Flow Cytometry Staining Buffer was added and repeated 
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the process. Cells were fixed in 2% PFA prior to imaging.  Cells were analyzed via LSR II/ 
LSRFortessa at UNC School of Medicine Flow Cytometry Core Facility. 
Luminex® Multiplex Assays 
 Cytokine expression analysis was performed using Luminex® Multiplex Assay 
(R&D Systems) at UNC Cytokine and Biomarker Analysis Facility. 
 THP-1 cell-derived DCs: Protein level of IL-29/IL-28B in the supernatant of culture 
media was quantified using the Human IL-29/IL-28B DuoSet ELISA (R&D Systems, 
Minneapolis, MN). Protein levels for pro and anti-inflammatory cytokines were analyzed by 
Human Magnetic Luminex Assay kit (R&D Systems, Minneapolis, MN) following 
manufacture’s instruction.  
 PBMC-derived DCs: After the completion of stimulation with TLR ligands, 
supernatant of culture medium was collected for Luminex® Multiplex Assay. The expression of 
IL-10 as anti-inflammatory marker and TNF-α as pro-inflammatory marker as well as IFN-λ2 
(IL-28A) and IFN-λ3 (IL-28B) was analyzed using Luminex Custom Multiplex Assay Kit (R&D 
Systems) in response to TLR ligands for 6 hours.  
Data analysis 
 Data distribution was tested for normality and skewness to assign appropriate 
nonparametric statistical tests, using a one tailed p value <0.05 for statistical significance. 
Differences between datasets were tested for cell culture experiments: by unpaired t-test (α = 
0.05) or Mann-Whitney rank sum test. Data for cytokine expression were analyzed by 
generalized linear model (GLM).  
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Results  
The expression of IL-29 mRNA in THP-1 cell-derived DCs  
We generated immature and mature DCs from THP-1 cell line according to established 
protocol. 10  First, we determined the capacity of THP-1 cell-derived DCs to produce IL-29. 
THP-cells were incubated in culture medium for 5 days and differentiated into immature 
dendritic cells. Immature DCs underwent maturation with 20ng/ml TNF-α and 200ng/ml 
ionomycin under continuous presence of IL-4 and GM-CSF for 6 hours. Maturing DCs were 
then stimulated with 100 ng/ml LPS from E. coli for 0 (no stimulation), 2, 6, and 18 hours. After 
stimulation with LPS, IL-29 mRNA levels were quantified with qRT-PCR. THP-1 cell-derived 
DCs expressed significantly higher levels of IL-29 in all time points of maturation compared that 
of immature DCs, with the highest mRNA level at 2-hour of maturation (38000-fold increase; 
figure 4). Though IL-29 mRNA levels at 6 and 18-hour time point decreased compared to that of 
DCs with 2-hour stimulation with LPS, mRNA expression levels were significantly higher than 
baseline. We then explored the protein expression levels for IL-28A and IL-28B in the same cells 
to obtain expression pattern of these cytokines in the protein level. Both IL-28A and IL-28B 
were minimally expressed in the cells without maturation. While IL-28A continued to increase 
the protein expression levels up to 18 hours, IL-28B showed the highest expression at 6-hour 
maturation (data not shown). 
IL-29 shRNA gene knockdown in THP-1 cell-derived DCs  
We then questioned the effect of IL-29 gene knockdown in the cytokine production after 
LPS stimulation. The knockdown efficiency of four sets of IL-29 shRNA on the mRNA 
expression levels of IL-29 was examined by qRT-PCR. As shown in figure 5, IL-29 mRNA 
expression was significantly lower compared to LPS stimulated DCs transduced with scramble 
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clone. This LPS-induced IL-29 mRNA upregulation was significantly suppressed in clone 58244 
(0.46-fold change), 58245 (0.31-fold change) and 582436 (0.28-fold change), while 58243 did 
not show significant knockdown effect (0.98 fold change) compared to DCs transduced with 
scramble clone (t-test, p<0.01). We therefore chose two of these clones, 58245 and 58246, for 
the subsequent cytokine analysis using Luminex® Multiplex Assay. 
The effect of IL-29 shRNA gene knockdown on cytokine production in response to LPS 
stimulation  
 
Next IL-29 gene knockdown effects in cytokine expression levels for IL-10, TNF-α, IL-
28A and IL-28B in the supernatant of culture medium were analyzed using Luminex® Multiplex 
Assay (figure 6). Unstimulated DCs expressed much less levels of IL-10 and TNF-α compared to 
LPS stimulated cells. Robust IL-10 expression was seen in response to LPS stimulation. 
Interestingly, the expression of IL-10 was decreased in clone 58245 and 58246 compared to 
scramble clone. TNF-α production was induced with LPS stimulation in all clones, but cells 
transduced with 582436 produced less amount of TNF-α after LPS stimulation. IL-28A cytokine 
was undetectable level in DCs without LPS stimulation, and was slightly increased in response to 
LPS challenge. However, there was no difference in the expression levels in eitgher clones 
compared scramble clone. IL-28B cytokine levels markedly increased after LPS stimulation in 
DCs, but the expression level was lower in the IL-29 shRNA knockdown DCs compared to 
scramble DCs (figure 6). 
PBMC derived DCs 
Subjects’ demographics were shown in table 1. After screening of study subjects who met 
inclusion criteria, a total of 79 subjects (age 25-71 y/o, average 42 y/o) were genotyped. Subjects 
who did not meet inclusion criteria were excluded from the study. Of those seventy-nine 
subjects, 15 subjects agreed to participate to blood drawing for PBMC.  
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Flow cytometric analysis for isolated CD14+/CD16lo PBMCs  
It is well known that the most abundant, classical subset of PBMCs, CD14+/CD16lo 
PBMCs, readily extravasate into tissues in response to inflammation where they can differentiate 
into DCs 12  13  14  15 , we determined to use this subset of cells in our experiment. CD14+/CD16lo 
PBMCs were negatively extracted using DynaBeads™ Untouched™ Human Monocytes Kit 
(Thermo Fisher Scientific). To assess the purity of isolated monocytes via after the negative 
extraction, flow cytometric analysis was employed: PBMCs were stained with APC anti-human 
CD14 antibody (BioLegend, San Diego, CA) and/or PE anti-human CD16 antibody (BioLegend, 
San Diego, CA). Flow cytometric analysis was performed on Becton Dickinson LSRFortessa at 
UNC FACS Core Facility. Purity of PBMCs was 94% and only small population (1.9%) co-
expressed CD16 with CD14 (figure 7). 
The effect of IL-29 and IL28B gene SNPs on the cytokine production in PBMC-derived DC in 
response to TLRs stimulation  
 
CD14+/CD16lo PBMCs were differentiated into immature DCs in the culture medium 
containing IL-4 and GM-CSF. Subsequently, these PBMC-derived DCs underwent maturation 
process with or without the addition of 100ng/ml LPS in the same culture medium containing IL-
4 and GM-CSF. After 6 hours, maturing DCs were imaged under the microscope, and confirmed 
that DCs with maturation morphologically differ from immature DCs, having distinctively 
extended dendrites (figure 8).  
PBMC-derived DCs from study subjects were divided in three groups: major allele for 
both IL-29 and IL-28B, major allele for IL-29 and minor allele for IL-28B, and minor allele for 
both IL-29 and IL-28B (figure 2). Medium was changed to fresh media only containing IL-4 and 
GM-CSF and cultured an additional 48 hours to prevent endotoxin tolerance.  16  17 Subsequently, 
PBMC-derived DCs were challenged with TLR-1/2, TLR-2 and TLR-4 ligands for 6 hours. As a 
 29 
control, cells were also cultured without maturation and/or stimulation with TLR ligands (figure 
9). Since the data were not normally distributed, all values were converted into log scale and 
generalized linear model was applied. There was significant increase in the IL-10 and TNF alpha 
expression levels in response to TLR2 and TLR4 stimulation. However, when compared between 
groups in each condition, there was no statistically significant difference. The expression pattern 
of IL-28A did not show any distinct pattern with no statistically significant difference with or 
without stimulation or between groups. Though IL-28B expression showed tendency to increase 
after TLRs stimulations, there was no statistically significant difference in the IL-28B levels 
except for TLR4 stimulation in dominant and minor allele group.  
Discussion 
In this study, we demonstrated that IL-29 knockdown suppressed the expression of IL-10 
and TNF-α in maturing DCs. To our knowledge, we demonstrate for the first time that IL-29 
gene knockdown using shRNA lentiviral particles suppresses both anti- and pro-inflammatory 
cytokine production in response to LPS in THP-1 cell-derived DCs. On the other hand, IL-29 
and IL-28B gene polymorphisms do not affect the amount of IL-10 and TNF-α produced by 
maturing PBMC-derived DCs after LPS stimulation. These novel findings suggest that the 
induction of IL-29 and IL-28B upon LPS stimulation regulate DC function of pro- and anti-
inflammatory cytokine production through autocrine signaling. The significance of gene 
polymorphisms in IL-29 and IL-28B may lie in the paracrine-signaling pathway in response to 
TLRs stimulation. 
Upregulation of IL-29 in response to LPS stimulation and its role in DC maturation 
The role of IL-29 in DCs in response to LPS stimulation has been reported by Wolk and 
colleagues previously. Maturing, but not immature or fully DCs are the major source of IL-29 in 
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response to activation of TLRs upon antigen binding, which signify the importance of IL-29 
expression in the DCs in regulating innate immunity in the neighboring environment. In the oral 
epithelial tissue at the interface with the oral cavity, DCs form a barrier of defense against 
constant microbial challenge. In homeostatic environment, immature DCs in the oral epithelial 
tissue migrated from peripheral tissue capture foreign objects or antigens, but do not become 
fully activated to enhance the T-cell mediated adaptive immune response. 18  On the other hand, 
when DCs recognize PAMPs through TLRs, immature DCs are activated and start maturing 
process 19 , migrate to local lymphoid organ, where they activate T-cell mediated immune 
response. Maturing DCs are highly capable of producing IL-29 and IL28B, which are critical for 
further differentiation and maturation of DCs. One of the main focuses of the present study was 
the role of IL-29 in this maturation process of DCs during innate immune response: we sought to 
define the relationship between IL-29 expression and pro- and anti-inflammatory cytokine 
production by THP-1 cell-derived DCs. Also we wanted to know the consequence when the 
amount of IL-29 was lowered in DCs. To answer these questions, we generated IL-29 gene 
knocked-down THP-1 cell using IL-29 shRNA lentiviral clones. Our data clearly showed that 
THP-1 cell-derived DCs produced significantly higher amount of IL-10 and TNF-α proteins in 
DCs transduced with scramble clone after LPS stimulation compared to DCs without LPS 
stimulation. However, this response was decreased in clones 58245 and 58256 for both IL-10 
and TNF-α. These findings suggest that IL-29 regulates the expression of IL-10 and TNF-α in 
DCs through autocrine manner.  
Previous studies have shown that the production of IL-10 during the maturation process 
can influence DC’s capacity to induce Th1 and Th2 immune response by blocking the maturation 
of DCs by interfering with upregulation of costimulatory molecules and production of IL-12, 
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resulting in the limited ability of DCs to initiate a Th1 response. 20  21  IL-10 produced by 
maturing DCs is able to function in an autocrine manner, and increased IL-10 expression by DCs 
limits LPS-mediated maturation of DCs. 21 Blocking IL-10 production by DCs induces type 1 
immunity, while unrestricted production of IL-10 by DCs may suppress unwanted type 1 
immune responses. Together with our results, IL-29 may regulate the maturing process of DCs 
through IL-10 production, and decreased IL-29 mRNA affected the ability of THP-1 cell-derived 
DCs to produce IL-10 in response to LPS. This altered expression of IL-10 may promote DC 
maturation and exaggerate Th1 response, enhancing inflammatory response. While IL-10 
suppresses DC maturation, TNF-α is a key molecule to mature DC efficiently during viral 
infection. The host immune response to intracellular pathogens relies on activation of the Th1 
pathway, and TNF-α expressed by DCs seems to play a critical role in this process. Both 
microbial stimulation and local TNF-α expression contribute to efficient maturation and 
migration of DCs. In the present study, IL-29 gene knockdown suppressed the production of 
TNF-α and affected the maturation process of DCs. Therefore, it is speculated that IL-29 plays a 
key role in regulating the initiation of inflammatory cascade by IL-10 and TNF-α and the antigen 
specific response.  
The receptor for type III IFNs are distinct from type I IFN, in terms of the composition of 
the receptor and the expression pattern. Unlike the ubiquitously expressed type I IFN receptor, 
expression of type III IFNs is epithelial cell specific, and leukocytes including monocytes do not 
usually express IFN-LR1. However, Mannechet and Uzé demonstrated that IFNL-R1 is 
upregulated during the DC differentiation and maturation in PBMC-derived DCs. Hence they are 
fully responsive to IFN-λs (IL-29, IL-28A and IL-28B). Through the receptor expressed by DCs, 
IFN-λs promotes capacity of maturing dendritic cells to trigger the proliferation of Foxp3-
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expressing CD4+ CD25+ T-cell subset, knows as regulatory T-cells. Regulatory T-cells suppress 
T-cell response and proliferation triggered by fully matured DCs. This process is critical for 
maintaining immunological self-tolerance and for suppressing immune responses. 22  Although 
this mechanism was not investigated in the present study, it is speculated that lower expression 
of IL-29 mRNA by DCs therefore has less potential to trigger the proliferation of regulatory T-
cells.  
The effect of gene polymorphisms in IL-29 and IL-28B 
Based on the result from THP-1 cell-derived DCs on IL-29 production as well as the 
observed effect on pro- and anti-inflammatory cytokine production in response to TLR-4 ligand 
stimulation, we further explored the role of IL-29 SNPs in the PBMC-derived DCs. In addition 
to TLR-4 ligand (LPS), additional TLR ligands, TLR-1/2 and TLR2 were tested as stimulants 
because of the fact that LPS from the most common periodontal pathogen, P. gingivalis, is 
recognized mainly by TLR-2. Consistent with our cell-line experiment, IL-10 was induced 
following TLR-4 ligand (LPS) stimulation as well as TLR-2 ligand (heat-killed L. 
monocytogene), but the effect was much larger in TLR-4 ligand stimulation. However, in the 
present study, gene polymorphisms in IL-29 and IL-28B did not affect either TNF-α or IL-10 
expression between groups in response to TLRs stimulation. This is probably due to the small 
sample size and the fact that three SNPs were pooled for IL-28B. Also the roles of these SNPs 
may not be within the regulation of IL-10 and TNF-α.  
There is accumulating evidence for a strong association of one of IL-28’s SNPs, 
rs8099917 in hepatitis C virus infection. 24  25  GWAS by a group in Switzerland using 1362 
patients (347 spontaneously cleared HCV, 1015 had progressed to persistent infection) has 
shown that several SNPs bear the IL-28 locus, and rs8099917as the top hit out of 500,000 SNPs 
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studied.  24  The results demonstrated that HCV infection minor allele genotype (T/G or G/G) has 
higher risk of treatment failure, and is considered as risk allele for the chronicity of disease The 
possible mechanism underlining this finding is that re8099917 may interfere with transcription 
factors and influence gene expression or splicing based on the location of rs8099917, 8kb 
upstream of the start codon of IL-28B. GWAS from Japanese group investigated 900,000 SNPs 
in a total of 154 Japanese patients with HCV (82 with null virologic response and 72 with 
virologic response). In this study, again, rs8099917 was found to have reached genome-wide 
level of significance. This study group further found six newly analyzed SNPs (rs12980275, 
rs8105790, rs118811222, rs8099917, rs7248668 and rs10853728) in their replication study, and 
four of them (rs8105790, rs118811222, rs8099917 and rs7248668) showed strongest associations 
with null virologic response (Two of those six SNPs, rs8105790 and rs8099917 found on the 
aforementioned GWAS were found to be significantly associated with severe periodontitis in the 
other GWAS 26 ). The frequencies of minor allele for rs8099917 positive patients were 75.6% in 
null virologic responders and 12.5% in virologic responders. In addition, homozygous miner 
allele genotype for rs8099917 was found only in null virologic response group. Real-time 
quantitative PCR assays in PBMCs of study subjects revealed a significantly lower level of IL-28 
mRNA expression in individuals with the minor alleles, suggesting that variant (s) regulating IL-
28 expression is associated with poor response to treatment. In vitro study 27  reported that IFN-λ 
exhibited dose- and time-dependent HCV inhibition. The kinetics of IFN-λ-mediated signal 
transducers and activators of transcription (STAT) activation and induction of potential effector 
genes were different from those of IFN-α. IFN-λ found to induces steady increases in levels of 
interferon stimulated genes (ISGs), while IFN-α ISGs peaks early and declines rapidly. It seems 
that one of the consequences of having minor alleles in those identified SNP(s) is a decreased 
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amount of IL-28 mRNA level compared to major allele genotypes, and this lower level of IL-28 
may affect the ISG production, which affect the synthesis of antiviral effectors, negative or 
positive gene regulators.  
IL-29 and IL-28B SNPs were also studied in several other inflammatory diseases such as 
systemic lupus 28 , psoriasis28 and rheumatoid arthritis. 29  Hashimoto’s thyroiditis is the most 
common autoimmune thyroid disease, primarily lymphocytic infiltration in the thyroid and 
increasing serum antibodies to thyroid-specific antigens, leading to destruction of thyrocytes and 
thyroid dysfunction. In PBMCs of autoimmune thyroid patients, increased serum levels of TNF-
α and IL-6 and decreased level of IL-10 synthesis have been reported.  30  It has been suggested 
that this imbalance between pro- and anti- inflammatory cytokines may play a role in the 
pathogenesis of Hashimoto’s thyroiditis. One of the critical pathological features of this disease 
is enhanced Th1 cell activity and decreased Th2 cell activity. Recent studies have shown that 
IFN-λs (IL-29, IL28A, IL-28B) have immunomodulatory effects such as regulation of dendritic 
cell maturation, T-cell and NK-cell cytotoxicity and Th1/Th2 response.  11  31  32  It is also 
suggested that IL-28B major allele genotype shows predominant polarizing to a macrophage M1 
phenotype, while the minor allele genotype may be associated with M2 phenotype, thereby 
indicating a great impact of IL-28B SNP on host immune response to infection.  33  Two SNPs 
related to IL-29 (rs30461) and IL-28B (rs8099917), both of which have also been found to be 
significantly associated with severe periodontitis in the other GWAS, were studied to explore the 
association between serum IL-29 and IL-28 levels and IL-29 and IL-28 gene SNPs in 
Hashimoto’s thyroiditis. 26  Elevated serum IL-28 and IL-29 were detected in Hashimoto’s 
thyroiditis patients, and higher proportion of rs8099917 TT (major) genotype and T allele were 
found among controls than disease cases, suggesting that T allele of IL-28 gene may act as a 
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protective allele in the pathogenesis of Hashimoto’s thyroiditis. However, no significant 
association was found between SNPs for IL-29 and Hashimoto’s thyroiditis.  
So far, two studies have investigated the correlation of SNPs in IL-29 and/or IL-28 genes 
in periodontal disease. Heidari and colleagues have reported the association of IL-28B SNP 
rs8099917 and IL-29 SNP rs12979680 in chronic periodontitis in Iranian population, 210 chronic 
periodontitis patients and 100 healthy controls. In this case control study, increased disease 
susceptibility was found in subjects with rs8099917 minor allele genotype (OR = 2.712) and 
rs12979680 minor allele genotype (OR = 2.538), and CT/GT, TT/GG and TT/GT haplotypes 
were predominant in chronic periodontitis patients. 34  The association of GCF IL-29 level and 
IL-29 SNP, rs30461 was studied among healthy, generalized chronic and aggressive 
periodontitis, however, in this particular study, no association was found in the IL-29 level in 
CGF based on the SNP variations of IL-29.  
Studies have shown the activation of IFN-λ in the other type of bacterial infection 
models: a study by Bierne and colleagues demonstrated activated IFN-λ genes by pathogenic 
bacteria in infected epithelial cells and mouse placenta placenta 35 . Authors reported that levels 
of IL-28A and IL-28B mRNA aas well as mRNA of the IFN-responsive genes IFIT1 and Mx1/2 
are increased in the placenta infected with L. monocytogenes, indicating that IFN-λ plays a role 
in the immune response at the fetoplacental barrier. However, they did not find whether the 
expression of IFN-λs could be beneficial to fetus from bacterial invasion or the acitvation of 
IFN-λs signaling pathway is beneficial for those bacterial pathogens.  The other interesting 
relationship of IFN-λ in bacterial infection is reported in the airway inflammation (such as 
pneumonia).  36  In this case, IFN-λs found to promote a prolonged inflammatory cytokine 
response to bacterial pathogens.  The mechanism behind this is that a major effector of IFN-λ 
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signaling is PDCD4 that influences production of proinflammatory signaling through its 
interaction with AP-1, NF-κB, and eIF4A. Another mechanism by which IFN-λ may be involved 
is that IFN-λs regulate barrier function of epithelium by enhancing epithelial cell integrity.  37 In 
virto study showed that enteric bacterial challenge increased tissue permeability measured as 
decrease in Trans Epithelial Electrical Resistance (TEER), but this was reversed by an addition 
of IFN-λs.  
Since periodontitis is inflammatory response by various types of immune cells and local 
resident cells to polymicrobial biofilm and some environmental factors, the mechanisms how our 
immune cells respond to bacterial biofim is far more complicated than that of in vitro studies. In 
addition, viral infection on top of bacterial infection cannot be excluded in the pathogenesis 
periodontitis. Therefore, above studies on the effect of SNPs in IFN-λ genes in viral infection, 
autoimmune diseases and bacterial infection as well as the effect of IFN-λs on neighboring 
epithelial tissue suggest that SNPs for IFN-λs have a vital role in host immune response in the 
pathogenesis of and in determining the susceptibility of periodontitis. 
There are certain limitations in our study. First, culturing single-cell type (for both cell 
line and primary cell culture) to detect the influence of SNPs in cytokine production via 
stimulation with TLR ligands may not mimic the true biologic and physiologic function of these 
genes, especially given the fact that IFN-λR1 is predominantly expressed in the cells of epithelial 
origin. It will be interesting to investigate co-culture with keratinocytes to see the effect on the 
cytokine production. It will be also interesting to investigate the IFN-LR1/IL10R2 receptor 
distribution pattern in the gingival tissue comparing healthy and periodontitis subjects using both 
human sample and animal models. In the future investigation, we also want to focus on the 
signaling pathway after the binding of ligands on IFN-λR1s on their receptors to see the effector 
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gene expressions and how they regulate the pro- and anti-inflammatory cytokine production and 
maintain balance between them in periodontal health or disease.   
CONCLUSIONS 
The present study demonstrated that IL-29 gene knockdown negatively affected the 
expression of TNF-α and IL-10 by THP-1 cell-derived DCs in response to LPS stimulation, 
suggesting a role for autocrine IL-29 signaling in the DC maturation. In addition, decreased 
expression levels of IL-28B in IL-29 gene knocked-down DCs in response to LPS stimulation 
suggests that IL-29 has regulatory effect on the expression of IL-28B, while IL-28A induction is 
independent of IL-29. Gene polymorphisms in IL-29 and IL-28B did not affect the expression of 
TNF-α or IL-10. Future studies are warranted for the significance of SNPs in IL-29 and IL-28 in 
the innate immune response in not only DCs but also other cell types. 
   
  
 38 
Table 1: Subjects demographics 
Subjects  
Study subjects Recruit from the local community and within UNC (N = 15) 
Ethnicity European American  
Age Average 42 y/o (range 25 – 71 y/o) 
 
 
 
Table 2: IL-29 and IL-28B SNPs 
 SNP Chromosome Major allele Minor allele MAF (%) 
IL-28B rs8105790 19:39241861 T C C=0.1727/865 
IL-28B rs1108359 19:39228623 A T T=0.3317/1661 
IL-28B rs8099917 19:39252525 T G G=0.1312/657 
IL-29 rs30461 19:39298475 T C G=0.2516/1260 
 
 
Table 3: The primers for genotyping 
Polymorphisms Prier Sequence (5’ è3’) Fragment size 
rs8105790 
 
Forward: CCCTTCCTGACATCACTCCA  
Reverse: GTCAGCATCATTAGCGGAAGA (Biotin) 
Sequencer: CCTGACATCACTCCAAT 
62bp 
rs1108359 Forward: CCCAGAAATAGACCCACACAAAT  
Reverse: TTGTGATCCACTTTTCTGCCTATA (Biotin) 
Sequencer: TGAGGAAGAATAGCCTTT  
139bp 
rs8099917 
 
Forward: TCATCCCACTTCTGGAACAAA  
Reverse: ATGTGGGAGAATGCAAATGAGA  (Biotin) 
Sequencer: TTTTCCTTTCTGTGAGC  
319bp 
rs30461 Forward:  CCTCACGCGAGACCTCAAATA 
Reverse:  GACTCAGGGTGGGTTGACG (Biotin) 
Sequencer: CGTTCTCAGACACAGGT  
69bp 
 
 
Table 4: IL-29 shRNA Lenriviral Clones 
Clone Number Sequence 
TRCN0000058243 CCGGGACCTCAAATATGTGGCCGATCTCGAGATCGGCCACATAT
TTGAGGTCTTTTTG 
TRCN0000058244 CCGGGCCACATTGGCAGGTTCAAATCTCGAGATTTGAACCTGCC
AATGTGGCTTTTTG 
TRCN0000058245 CCGGCTCACGCGAGACCTCAAATATCTCGAGATATTTGAGGTCT
CGCGTGAGTTTTTG 
TRCN0000058246 CCGGGAGTTGCAGCTCTCCTGTCTTCTCGAGAAGACAGGAGAGC
TGCAACTCTTTTTG 
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Figure 1: IFN-λs and SNPs in human genome 
 
 
 
 
 
Figure 2: Flow chart of inclusion and exclusion of study subjects. 1.1 = major allele/majoe 
allele, SNPs = having one of the minor allele (1.2 or 2.2). A total of 15 subjects enrolled.  
rs30461 (IL-29, T/C), rs8105790 (IL-28B, T/C), rs1108359 (IL-28B, A/T), rs8099917 (IL-28B, 
T/G).  
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Figure 3: PCR for IL-29 and IL-28B SNPs 
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Figure 4:  IL-29 mRNA expression during the maturation of THP-1 cell-derived DCs.  IL-
29 mRNA was extracted and reverse transcribed. Real-time PCR was performed using primers 
specific for human IL-29 with cDNA normalized to GAPDH expression. Immature DCs 
differentiated from THP-1 cells were primed with 100ng/ml LPS for 2, 6, and 18 hours to induce 
maturation of the cells. While significantly increased IL-29 mRNA level is seen at all time 
points, highest mRNA expression was seen in THP-1 cell-derived DCs with 2 hours of 
maturation. ** P<0.01. 
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Figure 5: IL-29 gene knockdown effect on THP-1 cell-derived DCs using shRNA. Numbers 
on X-axis, 58243, 58244, 58245, 58246 correspond to IL-29 knockdown clones 
TRCN0000058243, TRCN0000058244, TRCN0000058245 and TRCN0000058246, 
respectively. Scramble is a non-functional clone as a control. After transduction, cells were 
differentiated and matured for 6 hours, followed by LPS stimulation for 6 hours. IL-29mRNA 
expression in IL-29 knockdown clones and scramble clone was analyzed by quantitative RT-
PCR. The fold changes in expression of IL-29 are shown relative to scramble (non-functional 
clone). * P<0.01. 
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Figure 6: Expression of TNF-α, IL-10, IL-28A and IL-28B in THP-1 cell-derived DCs. 
Numbers on X-axis, 58245, 58246 correspond to IL-29 shRNA clones TRCN0000058245 and 
TRCN0000058246, respectively. Scramble (non-functional clone) serves as a control. A. TNF-α 
protein expression (pg/ml) in THP-1 cell-derived DCs. DCs transduced with scramble clone 
showed highest expression of TNF-α, while lower expression level seen in clone 58243, 58245 
and 58246. B. IL-10 protein expression (pg/ml) in THP-1 cell-derived DCs. Compared to 
scramble, DCs treated with IL-29 shRNA lentiviral clones showed lower expression levels of IL-
10. C. IL-28A protein expression (pg/ml) in THP-1 cell-derived DCs. LPS stimulation induced 
IL-28A expression. However, there was no difference in the expression levels between clones.  
D. IL-28B protein expression (pg/ml) in THP-1 cell-derived DCs. LPS stimulation induced 
expression of IL-28B. Highest expression in the DCs transduced with scramble clone. Decreased 
expression levels of IL-28B were seen in IL-29 gene knockdown DCs. 
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Figure 7: Flow cytometry for PBMCs. Dot plot show forward scatter versus side scatter of 
mononuclear cells obtained from PBMCs isolated with bead (negative) extraction. B. A 
monocyte gate is drawn and monocyte subsets are identified to their CD14 and CD16 expression 
profile. C. Table summarizes the expression rate of CD14+ and CD14+/CD16+ cells. 94.1% cells 
are pure CD14+ cells. 
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Figure 8:  Morphological difference between immature and maturing DCs was captured 
under microscope (20X).  A. DCs differentiated but no exposure to LPS. B. DCs differentiated 
and matured with 100ng/ml LPS for 6 hours. Multiple, elongated dendrites are evident in 
maturing DCs. Scale bar = 200µm.    
A B 
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Figure 9: The effect of gene polymorphisms of IL-29 and IL-28B on the expression of IL-
10, TNF-α, IL-28A and IL-28B in PBMC-derived DCs from 3 genotype groups: 1.1/1.1 = 
major allele for both IL-29 and IL-28B, 1.1/SNPs = major allele for IL-29, and at least 1 minor 
allele for IL-28B, 1.2/SNPs = minor allele for both IL-29 and IL-28B.  
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